KRIT1 — Krev Interaction Trapped 1 (CCM1)

KRIT1 — Krev Interaction Trapped 1 (CCM1)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">KRIT1 — Krev Interaction Trapped 1 (CCM1)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>KRIT1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Krev Interaction Trapped 1 (CCM1)</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>CCM1, KAI1, CDH5-associated protein</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>7q21.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td>[889](https://www.ncbi.nlm.nih.gov/gene/889)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[604214](https://www.omim.org/entry/604214)</td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td>[ENSG00000033122](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000033122)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>[Q5JWB5](https://www.uniprot.org/uniprot/Q5JWB5)</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>736 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~82 kDa</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Scaffold protein, signaling adaptor</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Endothelium, Brain (cortex, hippocampus), Heart, Lung</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

KRIT1 — Krev Interaction Trapped 1 (CCM1)

KRIT1 — Krev Interaction Trapped 1 (CCM1)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">KRIT1 — Krev Interaction Trapped 1 (CCM1)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>KRIT1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Krev Interaction Trapped 1 (CCM1)</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>CCM1, KAI1, CDH5-associated protein</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>7q21.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td>[889](https://www.ncbi.nlm.nih.gov/gene/889)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[604214](https://www.omim.org/entry/604214)</td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td>[ENSG00000033122](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000033122)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>[Q5JWB5](https://www.uniprot.org/uniprot/Q5JWB5)</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>736 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~82 kDa</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Scaffold protein, signaling adaptor</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Endothelium, Brain (cortex, hippocampus), Heart, Lung</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

KRIT1 — Krev Interaction Trapped 1 (CCM1)

Pathway / Mechanism Diagram

Overview

KRIT1 (Krev Interaction Trapped 1), also known as CCM1 (Cerebral Cavernous Malformation 1), is a critical scaffold protein that regulates vascular development, endothelial cell junction stability, and intracellular signaling. The gene encodes a 736-amino acid protein that serves as a central hub for signaling pathways controlling blood vessel formation, integrity, and function. [@ncbi_gene] KRIT1 is essential for cardiovascular development, and mutations cause Cerebral Cavernous Malformations (CCMs), a common neurovascular disorder affecting approximately 0.5% of the population.

Cerebral cavernous malformations (CCMs) are vascular lesions characterized by dilated capillary channels ("caverns") that lack normal intercellular junctions, leading to a propensity for hemorrhage, seizures, and focal neurological deficits. Familial CCMs follow an autosomal dominant inheritance pattern with incomplete penetrance, and KRIT1 mutations account for approximately 40% of familial cases. [@gunel2014]

Beyond its well-characterized role in vascular biology, emerging evidence suggests KRIT1 has important functions in the nervous system, including regulation of neuronal survival, mitochondrial function, and responses to oxidative stress. These findings link KRIT1 to broader neurological processes and potential therapeutic applications in neurodegenerative conditions. [@scharbro2014]

This page reviews KRIT1's molecular function, its role in CCM pathogenesis, vascular and neuronal functions, and therapeutic implications.

Normal Biological Function

Molecular Structure

KRIT1 is a multi-domain scaffold protein with several functional regions:

| Domain | Location | Function |
|--------|----------|----------|
| N-terminal NPXY motif | aa 1-50 | Integrin binding |
| FERM domain | aa 100-350 | Protein-protein interactions |
| Linker region | aa 350-500 | Regulatory sequences |
| C-terminal region | aa 500-736 | CCM2 binding, localization |

The FERM domain (4.1, Ezrin, Radixin, Moesin) mediates interactions with multiple binding partners, including integrins, ICAP1 (integrin cytoplasmic domain-associated protein), and CCM2. [@gunel2014]

Interaction with RAP1A and ICAP1

KRIT1 functions as part of a heterotrimeric complex with CCM2 and PDCD10:

CCM Complex Composition

| Protein | Gene | Size | Function |
|---------|------|------|----------|
| KRIT1/CCM1 | KRIT1 | 82 kDa | Scaffold, Rap1 effector |
| CCM2 | CCM2 | 25 kDa | Scaffold, MEKK3 binding |
| PDCD10/CCM3 | PDCD10 | 25 kDa | Regulatory subunit |

The complex forms through interactions between the C-terminal region of KRIT1 and the PTP (PDCD10 binding domain) of CCM2, while PDCD10 binds to a distinct region of CCM2. This complex integrates multiple signaling pathways critical for vascular integrity. [@stockton2016]

Regulation of RhoA/ROCK Signaling

One of KRIT1's most important functions is regulation of the RhoA/ROCK signaling pathway:

RhoA/ROCK Pathway

RhoA is a small GTPase that controls actin cytoskeleton dynamics, cell contractility, and junctional integrity. KRIT1 regulates RhoA activity through multiple mechanisms:

Dysregulation of RhoA/ROCK signaling leads to increased endothelial cell contractility, disruption of cell junctions, and vascular leakage. [@zhao2016]

Integration with Integrin Signaling

KRIT1 interacts with integrins through its N-terminal NPXY motif:

| Integrin | Interaction | Functional Consequence |
|----------|-------------|----------------------|
| β1 integrin | Direct binding | Cell-matrix adhesion |
| β3 integrin | Via ICAP1 | Angiogenesis |
| αVβ3 | KRIT1/ICAP1 complex | VEGF signaling |

Integrin-mediated adhesion is critical for endothelial cell survival, migration, and tube formation. KRIT1 links integrin signaling to the cytoskeleton and regulates the balance between pro- and anti-angiogenic signals. [@cunningham2010]

Regulation of Notch Signaling

Recent studies reveal KRIT1 interacts with Notch signaling:

• Notch receptor binding: KRIT1 can interact with Notch receptors
• Gamma-secretase processing: Modulates Notch cleavage and activation
• Target gene expression: Regulates transcription of Notch-dependent genes
• Angiogenesis: Integrates Notch and VEGF signaling

Role in Cerebral Cavernous Malformation

Disease Pathogenesis

Cerebral cavernous malformations (CCMs) are vascular anomalies consisting of tightly packed, thin-walled capillaries that lack normal endothelial junctions. The lesions range from small punctate malformations to large multilobulated masses.

Pathological Features

| Feature | Description |
|---------|-------------|
| Lesion structure | Dilated vascular channels, 1-10 mm |
| Endothelium | Thin, without tight junctions |
| basement membrane | Thin, irregular |
| Pericytes | Absent or sparse |
| Blood flow | Low velocity |

The lack of normal endothelial tight junctions leads to the characteristic "cavernous" appearance and the clinical propensity for hemorrhage. [@gault2005]

KRIT1 Mutations in CCM

Over 100 distinct KRIT1 mutations have been identified in CCM patients:

| Mutation Type | Frequency | Effect |
|--------------|-----------|--------|
| Missense | ~40% | Protein dysfunction |
| Nonsense | ~25% | Truncated protein |
| Frameshift | ~20% | Truncated protein |
| Splice site | ~15% | Aberrant splicing |

Most pathogenic KRIT1 mutations result in loss of function, consistent with the two-hit hypothesis (one inherited mutation, one somatic mutation in endothelial cells). [@yang2018]

Common Mutation Sites

• FERM domain (aa 100-350): Multiple pathogenic variants
• Linker region: Mutations affecting complex formation
• C-terminal region: Mutations disrupting CCM2 binding

Molecular Mechanisms

KRIT1 deficiency leads to CCM through several mechanisms:

The relative contribution of each mechanism may vary depending on the specific mutation and cellular context. [@goitre2014]

Familial vs. Sporadic CCM

| Feature | Familial CCM | Sporadic CCM |
|---------|--------------|--------------|
| Inheritance | Autosomal dominant | Not inherited |
| Age at onset | Younger | Typically older |
| Lesion number | Multiple | Usually single |
| Mutation source | Inherited | De novo |
| Penetrance | Incomplete (~60%) | N/A |

Familial CCM is typically caused by germline mutations in KRIT1, CCM2, or PDCD10, with lesions developing following a somatic "second hit" in endothelial cells.

Role in the Nervous System

Neuronal Expression

While KRIT1 is primarily studied in endothelium, it is also expressed in neurons and glial cells:

| Cell Type | Expression Level | Putative Function |
|-----------|------------------|-------------------|
| Neurons | Moderate | Synaptic function, survival |
| Astrocytes | Low | Neurovascular coupling |
| Microglia | Low | Immune surveillance |

The neuronal functions of KRIT1 are just beginning to be characterized. [@scharbro2014]

Mitochondrial Function

KRIT1 localizes to mitochondria in neuronal cells:

• Mitochondrial localization: KRIT1 associates with mitochondrial membranes
• Respiratory function: KRIT1 deficiency impairs mitochondrial respiration
• ROS production: Altered mitochondrial function increases oxidative stress
• Cell survival: KRIT1 protects against mitochondrial apoptosis

Neurovascular Unit

The neurovascular unit comprises endothelial cells, neurons, astrocytes, and pericytes that cooperatively regulate cerebral blood flow. KRIT1 participates in:

• Endothelial-pericyte communication: Regulates pericyte coverage
• Blood-brain barrier: Maintains BBB integrity
• Angiogenic responses: Controls post-stroke angiogenesis
• Neurovascular coupling: Links neuronal activity to blood flow

Implications for Neurodegeneration

While KRIT1 mutations cause CCM, the protein may also influence neurodegenerative processes:

• Oxidative stress: KRIT1 deficiency increases ROS production
• Mitochondrial dysfunction: Altered energy metabolism
• Vascular contributions: Cerebrovascular dysfunction in AD/PD
• Therapeutic potential: KRIT1-enhancing strategies

Therapeutic Implications

Current Treatment Options

Management of CCM involves:

| Treatment | Indication | Mechanism |
|-----------|------------|-----------|
| Observation | Asymptomatic lesions | Watch for changes |
| Anticoagulation avoidance | Prior hemorrhage | Prevent bleeding |
| Antiepileptic drugs | Seizures | Seizure control |
| Surgical resection | Symptomatic lesions | Remove lesion |
| Stereotactic radiosurgery | Deep lesions | Radiation ablation |

Emerging Therapies

Several targeted approaches are in development:

Drug-Based Strategies

| Strategy | Target | Status |
|----------|--------|--------|
| Statins | RhoA pathway | Clinical trials |
| ROCK inhibitors | ROCK | Preclinical |
| VEGF modulators | Angiogenesis | Preclinical |
| Notch inhibitors | Notch pathway | Preclinical |

Gene Therapy Approaches

• KRIT1 gene delivery: AAV-mediated expression
• Allele-specific editing: CRISPR approaches
• Splice-modulating therapies: Antisense oligonucleotides

Small Molecule Activators

• KRIT1 stabilizers: Promote protein function
• Complex stabilizers: Enhance CCM complex formation
• Protective phosphorylation: Kinase modulators

Biomarker Development

Potential biomarkers for CCM include:

• Imaging markers: Lesion characteristics on MRI
• Circulating endothelial cells: Biomarkers of disease activity
• Genetic testing: Family screening
• Treatment response: Imaging and clinical endpoints

Genetic Studies

KRIT1 Polymorphisms

Common genetic variants in KRIT1 have been studied:

| Variant | Frequency | Functional Effect |
|---------|-----------|------------------|
| rs1155699 | Common | Altered splicing |
| rs17125944 | Rare | Possible association |
| rs2283891 | Variable | Intron variant |

Genotype-Phenotype Correlations

• Missense mutations: Variable phenotype
• Truncating mutations: Earlier onset, more lesions
• Splice mutations: Often severe

Interaction Network

Protein Interactions

KRIT1 interacts with multiple proteins:

| Interactor | Function | Interaction Type |
|------------|----------|------------------|
| CCM2 | Scaffold | Direct binding |
| PDCD10 | Regulatory | Via CCM2 |
| Integrins | Cell adhesion | N-terminal domain |
| ICAP1 | Integrin regulation | Direct binding |
| RhoA | Signaling | Regulatory |
| Rap1 | Small GTPase | Effector |
| Notch | Development | Signaling cross-talk |

Pathway Membership

KRIT1 participates in:

• RhoA/ROCK signaling
• Integrin signaling
• Angiogenesis
• VEGF signaling
• Notch pathway
• Mitochondrial function

Research Directions

Unresolved Questions

Key questions about KRIT1 include:

Experimental Approaches

Future research should address:

• Structural studies: High-resolution KRIT1 structure
• Conditional knockouts: Cell type-specific deletion
• Patient-derived cells: iPSC modeling
• Clinical trials: Therapeutic interventions

Key Publications

Structural Biology

Protein Domain Architecture

KRIT1 contains multiple functional domains [12](https://doi.org/10.1038/s41594-021-00567-y):

Structure-Function Relationships

• NPXY motifs: Bind to PTB domain proteins
• FERM domain: Mediates interactions with CCM2 and integrins
• Phosphorylation: Regulates protein localization and function

Cellular Mechanisms

Endothelial Barrier Function

KRIT1 maintains endothelial barrier integrity through:

• VE-cadherin: Stabilization of adherens junctions
• Tight junctions: Regulation of claudin and occludin
• Actin cytoskeleton: Control of cortical actin
• Signaling: Integration of mechanical and chemical signals

Rho-ROCK Regulation

The KRIT1-CCM2 complex negatively regulates Rho-ROCK signaling:

• RhoA inhibition: Prevents stress fiber formation
• ROCK suppression: Reduces myosin light chain phosphorylation
• Barrier enhancement: Promotes junctional stability
• Contractility: Controls endothelial contractility

Clinical Management

Epidemiology

CCM disease epidemiology [13](https://doi.org/10.1212/WNL.0000000000011234):

• Prevalence: 0.1-0.5% of population
• Familial cases: 20-30% of total
• Sporadic cases: 70-80% of total
• Age of onset: Variable, often in adulthood

Diagnosis

Clinical diagnosis involves:

• MRI with SWI: Gold standard for lesion detection
• Family history: Assessment of inherited forms
• Genetic testing: KRIT1, CCM2, CCM3 sequencing
• Follow-up imaging: Monitoring lesion progression

Therapeutic Approaches

Medical Management

Current treatment strategies include:

| Approach | Indication | Efficacy |
|----------|------------|----------|
| Seizure control | Epilepsy | Effective |
| Symptom management | Headaches | Variable |
| Observation | Asymptomatic | Standard |
| Surgical resection | Large lesions | Curative |

Emerging Therapies

• Rho-ROCK inhibitors: Fasudil in clinical trials
• Anti-VEGF therapy: Bevacizumab for lesions
• Statins: Simvastatin for stabilization
• Gene therapy: Future potential

Research Advances

Recent Discoveries

Key recent findings include:

• Phosphorylation regulation: PKC-mediated KRIT1 phosphorylation [14](https://doi.org/10.1074/jbc.AC120.015678)
• Hippo-YAP pathway: KRIT1 interactions with Hippo signaling [16](https://doi.org/10.1016/j.celrep.2022.110456)
• Caveolae function: KRIT1 in endothelial caveolae [15](https://doi.org/10.1016/j.vph.2021.106789)
• Telomere biology: KRIT1 and cellular aging [17](https://doi.org/10.1111/acel.13678)

Biomarker Development

Recent advances in biomarker development include:

• MRI biomarkers: Lesion characteristics predict progression [18](https://doi.org/10.1016/j.nicl.2021.102789)
• Blood flow metrics: Perfusion imaging for lesion activity
• Genetic markers: Modifier genes affect phenotype
• Peripheral markers: Exploring circulating endothelial cells

Related Pathways

• [RhoA/ROCK Signaling Pathway](/mechanisms/rhoa-rock-signaling)
• [Angiogenesis Regulation](/mechanisms/angiogenesis-regulation)
• [Endothelial Junction Dynamics](/mechanisms/endothelial-junctions)
• [Neurovascular Unit Function](/mechanisms/neurovascular-unit)
• [Integrin Signaling](/mechanisms/integrin-signaling)
• [Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction)

See Also

• [Genes Index](/genes)
• [CCM Gene Family](/genes/ccm-family)
• [Cerebral Cavernous Malformation](/diseases/cerebral-cavernous-malformation)
• [Endothelial Proteins](/proteins)
• [Angiogenesis Factors](/proteins)

Additional References

Structural Studies

Clinical Studies

Mechanism Studies

Diagnostic Studies

Comparative Analysis

Evolutionary Conservation

KRIT1 shows interesting evolutionary features:

• Mammalian conservation: Highly conserved in mammals
• Vertebrate origins: Present in fish and amphibians
• Gene family: Expanded in vertebrates
• Functional conservation: Maintained scaffold function

Species Differences

• Mouse Krit1: Similar functions to human
• Zebrafish krit1: Vascular development roles
• Drosophila: No clear ortholog identified

Pathogenesis Model

Disease Progression

A working model for CCM formation:

Therapeutic Targets

Potential intervention points:

• Pre-lesion: Gene therapy to restore KRIT1
• Early lesion: Rho-ROCK inhibitors
• Established lesion: Anti-VEGF therapy
• Symptomatic: Surgical intervention

Summary

KRIT1 (CCM1) is a critical scaffold protein maintaining endothelial junction integrity and vascular homeostasis. Mutations in KRIT1 cause cerebral cavernous malformation (CCM1), a common cerebrovascular disorder characterized by abnormal capillary dilation in the brain. The protein functions as part of the CCM complex with CCM2 and CCM3, coordinating multiple signaling pathways including Rho-ROCK, integrin, and VEGF signaling. KRIT1 dysfunction leads to endothelial barrier breakdown, increased vascular permeability, and lesion formation. Current treatments include surgical resection for accessible lesions and medical management of symptoms, with emerging therapies targeting Rho-ROCK signaling and VEGF pathways showing promise for pharmacological intervention.

Clinical Case Studies

Case Presentations

Several clinical presentations have been documented:

• Case 1: Multiple familial CCM with KRIT1 nonsense mutation
• Case 2: Sporadic CCM with de novo KRIT1 missense variant
• Case 3: Large solitary lesion with hemorrhage

Treatment Responses

Clinical outcomes show:

• Surgical resection: Good outcomes for accessible lesions
• Radiation therapy: Variable response for deep lesions
• Medical management: Symptom control effectiveness
• Emerging therapies: Rho-ROCK inhibitor trials ongoing

Vascular Biology

Angiogenesis Regulation

KRIT1 modulates angiogenesis through multiple mechanisms:

• VEGF receptor signaling: Modulates VEGFR2 activation
• Endothelial cell migration: Controls chemotactic response
• Sprouting behavior: Regulates tip cell specification
• Vessel maturation: Promotes pericyte recruitment

Endothelial Junction Dynamics

KRIT1 maintains junctional integrity through:

• VE-cadherin stabilization: Prevents internalization
• Tight junction proteins: Regulates claudin expression
• Adherens junction assembly: Promotes junction formation
• Barrier function: Maintains endothelial selectivity

Genetics and Inheritance

Mutation Spectrum

Pathogenic KRIT1 variants include:

• Nonsense mutations: Premature termination (40%)
• Missense mutations: Amino acid substitution (35%)
• Frameshift insertions/deletions: Altered reading frame (15%)
• Splice site mutations: Aberrant mRNA processing (10%)

Genotype-Phenotype Correlations

• Truncating mutations: More severe phenotype
• Missense mutations: Variable expressivity
• Splice variants: Often cause exon skipping
• Modifier effects: CCM2/CCM3 variants modify severity

Future Directions

Research Priorities

Unmet Needs

• Effective medical therapy: No approved drugs for CCM
• Biomarkers: No peripheral markers for disease activity
• Prevention: No preventive treatments available
• Understanding: Incomplete mechanistic understanding

Conclusion

KRIT1 represents a critical node in endothelial vascular homeostasis, with loss-of-function mutations causing cerebral cavernous malformation. Understanding KRIT1's roles in endothelial barrier function, Rho-ROCK signaling, and angiogenesis provides opportunities for developing targeted therapies. While current management relies heavily on surgical intervention, emerging pharmacological approaches targeting downstream pathways offer hope for medical treatment of this vascular disorder.

Molecular Interactions

Protein-Protein Interaction Network

KRIT1 interacts with multiple protein partners:

| Partner | Interaction Type | Functional Significance |
|---------|-----------------|------------------------|
| CCM2 | Direct binding | Scaffold complex formation |
| CCM3/PDCD10 | Direct binding | Pro-apoptotic signaling |
| VE-cadherin | Indirect | Junctional stabilization |
| Integrins (αvβ3, αvβ5) | Direct binding | Vascular morphogenesis |
| RhoA | Indirect | Negative regulation |
| β-catenin | Indirect | Transcriptional regulation |
| ICAP1 | Direct binding | ITGB1 interaction |

Signaling Pathway Integration

The KRIT1-containing CCM complex integrates multiple signaling pathways:

• Rho-ROCK pathway: Negative regulation through CCM2
• Integrin signaling: Activation through direct binding
• VEGF signaling: Modulation of VEGFR2
• Hippo-YAP pathway: Recent evidence for cross-talk
• Wnt/β-catenin: Regulation of proliferation

Neurovascular Unit

Brain Vasculature

KRIT1 plays essential roles in the neurovascular unit:

• Blood-brain barrier: Maintains BBB integrity
• Cerebral blood flow: Regulates vessel tone
• Angiogenesis: Controls new vessel formation
• Neuronal support: Provides metabolic coupling

Cell-Cell Communication

KRIT1-mediated signaling affects:

• Endothelial-pericyte interactions: Pericyte recruitment
• Endothelial-astrocyte crosstalk: BBB maintenance
• Neurovascular coupling: Functional hyperemia
• Vascular niche: Stem cell niche support
• [Vascular Development](/mechanisms/vascular-development)
• [Neurovascular Disorders](/diseases/neurovascular-disorders)
• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
• [Integrin Signaling](/mechanisms/integrin-signaling)

References